Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...

ORG Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 108.2% ...

ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis ...

In North America, Europe and Australia alone there are more than 22,000 people aged 12 and older who have two copies of the F508del mutation. Vertex expects to file for approval of the combination ...

Vertex has reached an agreement with the Swedish health system to reimburse Orkambi, the first medicine to treat the underlying cause of cystic fibrosis in people with two copies of the F508del ...

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

coded as 0 or 1 according to whether pancreatic enzyme supplements were ever prescribed), genotype (coded as the number of F508del alleles (0, 1 or 2)), sex, ethnicity (white/other) and diagnosis by ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.